Matthew Harrison
Stock Analyst at Morgan Stanley
Total Price Targets
30
Stocks Covered
15
Sectors
Healthcare
Most Recent
Aug 1, 2025
Notable Calls (Last 12 Months)
Stocks Covered by Matthew Harrison
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | $32.00 | $44.65 | -28.3% | 7 | Aug 1, 2025 |
| AVIR | Atea Pharmaceuticals, Inc. | $6.88 | $5.60 | +22.9% | 1 | Aug 12, 2024 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $8.00 | $4.09 | +95.6% | 1 | Jun 18, 2024 |
| BIIB | Biogen Inc. | $331.00 | $186.69 | +77.3% | 3 | May 22, 2024 |
| EDIT | Editas Medicine, Inc. | $7.00 | $2.91 | +140.6% | 2 | May 9, 2024 |
| SRPT | Sarepta Therapeutics, Inc. | $165.00 | $21.60 | +663.9% | 2 | May 6, 2024 |
| REGN | Regeneron Pharmaceuticals, Inc. | $1115.00 | $703.72 | +58.4% | 4 | Mar 13, 2024 |
| ADCT | ADC Therapeutics S.A. | $11.00 | $3.82 | +188.0% | 1 | Sep 9, 2022 |
| VRTX | Vertex Pharmaceuticals Incorporated | $250.00 | $425.06 | -41.2% | 2 | May 3, 2022 |
| BMRN | BioMarin Pharmaceutical Inc. | $113.00 | $54.20 | +108.5% | 2 | Apr 25, 2022 |
| JNJ | Johnson & Johnson | $173.00 | $227.97 | -24.1% | 1 | Apr 11, 2022 |
| BMY | Bristol-Myers Squibb Company | $66.00 | $58.22 | +13.4% | 1 | Mar 28, 2022 |
| GILD | Gilead Sciences, Inc. | $69.00 | $132.04 | -47.7% | 1 | Feb 24, 2022 |
| LLY | Eli Lilly and Company | $265.00 | $961.67 | -72.4% | 1 | Feb 6, 2022 |
| TSHA | Taysha Gene Therapies, Inc. | $39.00 | $6.38 | +511.3% | 1 | Oct 19, 2021 |
Recent Activity
- Aug 1, 2025— Set$32.00price target onMRNA(Moderna, Inc.)
- Sep 12, 2024— Set$94.00price target onMRNA(Moderna, Inc.)
- Aug 12, 2024— Set$6.88price target onAVIR(Atea Pharmaceuticals, Inc.)
- Jun 18, 2024— Set$8.00price target onZNTL(Zentalis Pharmaceuticals, Inc.)
- May 22, 2024— Set$331.00price target onBIIB(Biogen Inc.)
- May 9, 2024— Set$7.00price target onEDIT(Editas Medicine, Inc.)
- May 6, 2024— Set$165.00price target onSRPT(Sarepta Therapeutics, Inc.)
- May 2, 2024— Set$95.00price target onMRNA(Moderna, Inc.)
- Apr 24, 2024— Set$89.00price target onMRNA(Moderna, Inc.)
- Mar 13, 2024— Set$1115.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Feb 22, 2024— Set$123.00price target onMRNA(Moderna, Inc.)
- Mar 1, 2023— Set$187.00price target onSRPT(Sarepta Therapeutics, Inc.)
- Sep 28, 2022— Set$285.00price target onBIIB(Biogen Inc.)
- Sep 9, 2022— Set$851.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Sep 9, 2022— Set$11.00price target onADCT(ADC Therapeutics S.A.)
- Aug 15, 2022— Set$625.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- May 4, 2022— Set$199.00price target onMRNA(Moderna, Inc.)
- May 3, 2022— Set$250.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Apr 25, 2022— Set$113.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Apr 11, 2022— Set$173.00price target onJNJ(Johnson & Johnson)
Frequently Asked Questions
Who is Matthew Harrison?
Matthew Harrison is a stock analyst at Morgan Stanley covering 15 stocks primarily in Healthcare. They have issued 30 price targets since Oct 19, 2021.
What stocks does Matthew Harrison cover?
Matthew Harrison currently covers 15 stocks, including MRNA, REGN, BIIB, EDIT, SRPT.
What is Matthew Harrison's latest price target?
Matthew Harrison's most recent price target was $32.00 on MRNA (Moderna, Inc.), set on Aug 1, 2025.
What is Matthew Harrison's highest price target?
Matthew Harrison's highest issued price target is $1115.00 on REGN, set on Mar 13, 2024.
More Analysts at Morgan Stanley
Coverage based on publicly published price targets. Not investment advice.